Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.72 |
| ▸ | MAOA | P21397 | 8/20 | 0.56 |
| ▸ | KDM1A | O60341 | 13/20 | 0.56 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17173900 | 1.00 | MAOB (0.72) | MAOBMAOAKDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL17159290 | 0.99 | MAOB (0.70) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL17159005 | 0.90 | MAOB (0.73) | MAOBMAOAKDM1A | |
| Hydrochloric Acid SCHEMBL17159351 | 0.89 | MAOB (0.72) | MAOBMAOAKDM1A | |
| SCHEMBL17159264 | 0.87 | MAOB (0.74) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL17173899 | 0.87 | MAOB (0.74) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL17158759 | 0.86 | MAOB (0.83) | MAOBMAOAKDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL17159091 | 0.86 | MAOB (0.73) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL17159253 | 0.84 | MAOB (0.69) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL17159141 | 0.84 | MAOB (1.00) | MAOBMAOAKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127775-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | ULTRAGENYX PHARMACEUTICAL INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230127775-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | ULTRAGENYX PHARMACEUTICAL INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127775-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | GAA, LIPA, TTR | MAOB 236/4885MAOA 317/4885KDM1A 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.